Mazdutide
A dual GLP-1 / glucagon receptor agonist developed by Innovent and Eli Lilly for type 2 diabetes and weight loss.
Overview
Mazdutide is a synthetic peptide that simultaneously activates GLP-1 and glucagon receptors. The glucagon arm contributes additional energy expenditure on top of GLP-1's appetite-suppressing effects, producing strong weight-loss results in trials primarily run in Asian populations.
Benefits
- Significant weight loss in trials
- Improved glycemic control
- Glucagon arm increases energy expenditure
- Once-weekly administration
Mechanism of Action
Dual activation of GLP-1 and glucagon receptors. GLP-1 suppresses appetite and improves insulin response, while glucagon increases lipolysis and metabolic rate.
Dosage (informational only)
- Typical range
- 3–9 mg per week (trial range)
- Frequency
- Weekly subcutaneous administration
Currently investigational outside of select markets.
Side Effects
- Nausea and vomiting
- Decreased appetite
- Possible elevated heart rate
- Diarrhea or constipation
Related peptides
A long-acting GLP-1 receptor agonist studied for its effects on appetite, satiety, and glucose regulation.
A dual GIP and GLP-1 receptor agonist with strong effects on appetite, glucose handling, and body composition.
An investigational triple agonist of GLP-1, GIP, and glucagon receptors producing some of the largest weight-loss results recorded in trials.